Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer

Jean Ogier du Terrail & Armand Leopold & Clément Joly & Constance Béguier & Mathieu Andreux & Charles Maussion & Benoît Schmauch & Eric W Tramel & Etienne Bendjebbar & Mikhail Zaslavskiy & Gilles Wainrib & Maud Milder & Julie Gervasoni & Julien Guerin & Thierry Durand & Alain Livartowski & Kelvin Moutet & Clément Gautier & Inal Djafar & Anne-Laure Moisson & Camille Marini & Mathieu Galtier & Félix Balazard & Rémy Dubois & Jeverson Moreira & Antoine Simon & Damien Drubay & Magali Lacroix-Triki & Camille Franchet & Guillaume Bataillon & Pierre-Etienne Heudel

Astract

Triple-negative breast cancer (TNBC) is a rare cancer, characterized by high metastatic potential and poor prognosis, and has limited treatment options. The current standard of care in nonmetastatic settings is neoadjuvant chemotherapy (NACT), but treatment efficacy varies substantially across patients. This heterogeneity is still poorly understood, partly due to the paucity of curated TNBC data. Here we investigate the use of machine learning (ML) leveraging whole-slide images and clinical information to predict, at diagnosis, the histological response to NACT for early TNBC women patients. To overcome the biases of small-scale studies while respecting data privacy, we conducted a multicentric TNBC study using federated learning, in which patient data remain secured behind hospitals’ firewalls. We show that local ML models relying on whole-slide images can predict response to NACT but that collaborative

rss facebook x github gitlab youtube mail spotify lastfm instagram linkedin google google-plus pinterest medium googlescholar cv vimeo stackoverflow reddit quora quora